When politicians subordinate scientific institutions to electoral interests, they undermine immediate public health efforts ...

In the EU, the AI Act has been approved, carrying significant implications for medical device, technology, and pharmaceutical firms. In the US, ...

The US Food and Drug Administration has released draft guidance on protocol deviations, but experts say it could go further.

Robert F. Kennedy Jr., President Donald Trump's pick to lead the top U.S. health agency, told U.S. senators during his ...

Robert F. Kennedy Jr. vows to finalize regulations for greater diverse patient involvement in clinical trials during his ...

Robert F. Kennedy Jr. may soon be America's top pharmaceutical regulator. That is cause for concern in Seattle’s biotech ...

President Donald Trump’s recently issued executive order (EO) putting a stop to diversity, equity, and inclusion programs in the U.S. government is sending ripples far and wide, into areas that some ...

The US Food and Drug Administration (FDA) recently issued a notice of noncompliance to the FADOI Foundation, citing the organization’s failure ...

In the United States, the biomedical industry encounters numerous regulatory challenges in conducting nonclinical and ...

In this video interview, Dipanwita Das, CEO & co-founder at Sorcero, highlights increased data management, DE&I, and ...

The IRA’s price controls discourage post-marketing research. The potential benefits from expanding access to the drug to patients with other diseases will be lost.

A clinical trial within the scope of the UK Medicines for Human Use (Clinical Trials) Regulations 2004. An investigation in human subjects intended: a) to discover or verify the clinical, ...